Obesity science & practice

Negative Effects of Losing Obesity Drug Coverage for GLP-1 Treatments: A Group Comparison Study

Updated

Abstract

Essence

Loss of employer GLP-1 obesity coverage was linked to poorer employee perceptions, , and turnover concerns.

Evidence

A cross-sectional cohort comparison analyzed 247 healthcare-system employees prescribed GLP-1 medications for obesity after coverage was discontinued, using survey outcomes and logistic regression.

Caveat

Because outcomes were self-reported after one employer's coverage change, the study cannot show whether coverage loss caused burnout or actual job changes.

Simplified

Key numbers

80.57%
Negative Impact on Employer Relationship
Percentage of employees reporting negative feelings after losing GLP-1 RA coverage.
17.81%
Consideration of Job Change
Percentage of employees considering changing jobs due to coverage loss.
88.67%
Prevalence
Percentage of employees reporting in the past year.

Full Text

What this is

  • This study examines the effects of losing GLP-1 receptor agonist (GLP-1 RA) coverage on employee perceptions and workplace dynamics.
  • Data were collected from 247 employees who lost coverage for GLP-1 medications aimed at treating obesity.
  • Findings indicate that loss of coverage correlates with negative feelings toward employers, increased , and higher turnover risk.

Essence

  • Loss of GLP-1 RA coverage negatively impacts employee satisfaction and increases , raising concerns about workforce stability.

Key takeaways

  • 80.57% of employees reported a negative impact on their relationship with their employer after losing GLP-1 RA coverage. This suggests a significant decline in workplace morale.
  • 17.81% of employees considered changing jobs due to the loss of coverage, indicating a potential increase in turnover risk.
  • 88.67% of participants experienced in the past year, which may further affect productivity and job satisfaction.

Caveats

  • The cross-sectional design limits causal inference, restricting the ability to determine long-term effects of coverage loss.
  • Self-reported data may introduce bias, as responses could be influenced by personal perceptions and experiences.
  • The study's single-site sample may limit the generalizability of findings to broader populations.

Definitions

  • GLP-1 receptor agonists (GLP-1 RAs): Medications that mimic the action of the glucagon-like peptide-1 hormone, promoting weight loss and improving obesity-related health issues.
  • Burnout: A state of emotional, physical, and mental exhaustion caused by prolonged and excessive stress, often leading to decreased motivation and productivity.

Simplified

Funding

Competing interests

1 of 10
authors report competing interests
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free